bluuebunny/crossref_metadata_2025_split huggingface dataset:
Internet‐Based Chat Support Groups for Parents in Family‐Based Treatment for Adolescent Eating Disorders: A Pilot Study
Authors: Binford Hopf Roslyn B. , Grange Daniel Le , Moessner Markus , Bauer Stephanie 
Published: September 2012

AbstractObjectiveThis study aims to examine the feasibility and acceptability of an Internet‐based chat support group for parents implementing family‐based treatment (FBT).MethodParticipants (N = 13) were parents of adolescents with eating disorder who participated in 15 weekly online therapist‐guided chat sessions. Sessions focused on encouraging and supporting parental efforts to help their child overcome an eating disorder.ResultsChat programme satisfaction ratings were high (91.7%). Participants reported looking forward to chat sessions and would recommend the chat to others. The vast majority reported that the chat helped them cope with their child's eating disorder and to implement FBT. Participants reported feeling that they could talk openly and honestly in sessions and had a sense of belonging to the group. Relatively few technical problems were reported, and the chat was rated as accessible, convenient and easy to use.DiscussionFindings provide preliminary support for the utility of an online parent chat as an adjunct to FBT. Copyright © 2012 John Wiley & Sons, Ltd and Eating Disorders Association.
Diurnal timing of warmer air under climate change affects magnitude, timing and duration of stream temperature change
Authors: Diabat Mousa , Haggerty Roy , Wondzell Steven M. 
Published: September 2012

AbstractStream temperature will be subject to changes because of atmospheric warming in the future. We investigated the effects of the diurnal timing of air temperature changes – daytime warming versus nighttime warming – on stream temperature. Using the physically based model, Heat Source, we performed a sensitivity analysis of summer stream temperatures to three diurnal air temperature distributions of +4 °C mean air temperature: i) uniform increase over the whole day, ii) warmer daytime and iii) warmer nighttime. The stream temperature model was applied to a 37‐km section of the Middle Fork John Day River in northeastern Oregon, USA. The three diurnal air temperature distributions generated 7‐day average daily maximum stream temperatures increases of approximately +1.8 °C ± 0.1 °C at the downstream end of the study section. The three air temperature distributions, with the same daily mean, generated different ranges of stream temperatures, different 7‐day average daily maximum temperatures, different durations of stream temperature changes and different average daily temperatures in most parts of the reach. The stream temperature changes were out of phase with air temperature changes, and therefore in many places, the greatest daytime increase in stream temperature was caused by nighttime warming of air temperatures. Stream temperature changes tended to be more extreme and of longer duration when driven by air temperatures concentrated in either daytime or nighttime instead of uniformly distributed across the diurnal cycle. Copyright © 2012 John Wiley & Sons, Ltd.
Response of streamflow to climate change and human activity in Xitiaoxi river basin in China
Authors: Zhang Canqiang , Zhang Biao , Li Wenhua , Liu Moucheng 
Published: September 2012

AbstractIn recent years, the Xitiaoxi river basin in China has experienced intensified human activity, including city expansion and increased water demand. Climate change also has influenced streamflow. Assessing the impact of climate variability and human activity on hydrological processes is important for water resources planning and management and for the sustainable development of eco‐environmental systems. The non‐parametric Mann–Kendall test was employed to detect the trends of climatic and hydrological variables. The Mann–Kendall–Sneyers test and the moving t‐test were used to locate any abrupt change of annual streamflow. A runoff model, driven by precipitation and potential evapotranspiration, was employed to assess the impact of climate change on streamflow. A significant downward trend was detected for annual streamflow from 1975 to 2009, and an abrupt change occurred in 1999, which was consistent with the change detected by the double mass curve test between streamflow and precipitation. The annual precipitation decreased slightly, but upward trends of annual mean temperature and potential evapotranspiration were significant. The annual streamflow during the period 1999–2009 decreased by 26.19% compared with the reference stage, 1975–1998. Climate change was estimated to be responsible for 42.8% of the total reduction in annual streamflow, and human activity accounted for 57.2%. Copyright © 2012 John Wiley & Sons, Ltd.
Effects of the Three Gorges Reservoir on the hydrological droughts at the downstream Yichang station during 2003–2011
Authors: Li Shuai , Xiong Lihua , Dong Leihua , Zhang Jun 
Published: September 2012

AbstractSince the Three Gorges Reservoir (TGR) was put into operation in June 2003, the effects of the TGR on downstream hydrology and water resources have become the focus of public attention. This article examines the effects of the TGR on the hydrological droughts at the downstream Yichang hydrological station during 2003–2011. The two‐parameter monthly water balance model was used to generate the monthly discharges at the Yichang station for the period of 2003–2011 to represent the unregulated flow regime and thus to provide a comparison benchmark for the observed flow series at the Yichang station after the operation of the TGR. To provide a reference series for the observed monthly discharge series of the entire study period of 1951–2011, we constructed the naturalized monthly discharge series at the Yichang station by joining the observed monthly discharge at the Yichang station for the period of 1951–2002 and the two‐parameter monthly water balance simulated monthly runoff at the Yichang station for the period of 2003–2011. For both the observed and naturalized monthly discharge series of 1951–2011, the hydrological drought index series were calculated using the standardized streamflow index method. By comparing the drought indices of these two monthly discharge series, we investigated the effects of the TGR on the hydrological droughts at the downstream Yichang station during 2003–2011. The results show that the hydrological droughts at the downstream Yichang station are slightly aggravated by the TGR's initial operation from 2003 to 2011. The river flow reduction at the Yichang station after impoundment of the TGR might account for the downstream drought aggravation. Copyright © 2012 John Wiley & Sons, Ltd.
A method for estimating spatially variable seepage and hydraulic conductivity in channels with very mild slopes
Authors: Shanafield Margaret , Niswonger Richard G. , Prudic David E. , Pohll Greg , Susfalk Richard , Panday Sorab 
Published: September 2012

AbstractInfiltration along ephemeral channels plays an important role in groundwater recharge in arid regions. A model is presented for estimating spatial variability of seepage due to streambed heterogeneity along channels based on measurements of streamflow‐front velocities in initially dry channels. The diffusion‐wave approximation to the Saint‐Venant equations, coupled with Philip's equation for infiltration, is connected to the groundwater model MODFLOW and is calibrated by adjusting the saturated hydraulic conductivity of the channel bed. The model is applied to portions of two large water delivery canals, which serve as proxies for natural ephemeral streams. Estimated seepage rates compare well with previously published values. Possible sources of error stem from uncertainty in Manning's roughness coefficients, soil hydraulic properties and channel geometry. Model performance would be most improved through more frequent longitudinal estimates of channel geometry and thalweg elevation, and with measurements of stream stage over time to constrain wave timing and shape. This model is a potentially valuable tool for estimating spatial variability in longitudinal seepage along intermittent and ephemeral channels over a wide range of bed slopes and the influence of seepage rates on groundwater levels. Copyright © 2012 John Wiley & Sons, Ltd.
Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial
Authors: Tran Ben , Brown Andrew M.K. , Bedard Philippe L. , Winquist Eric , Goss Glenwood D. , Hotte Sebastien J. , Welch Stephen A. , Hirte Hal W. , Zhang Tong , Stein Lincoln D. , Ferretti Vincent , Watt Stuart , Jiao Wei , Ng Karen , Ghai Sangeet , Shaw Patricia , Petrocelli Teresa , Hudson Thomas J. , Neel Benjamin G. , Onetto Nicole , Siu Lillian L. , McPherson John D. , Kamel‐Reid Suzanne , Dancey Janet E. 
Published: September 2012

AbstractThe successes of targeted drugs with companion predictive biomarkers and the technological advances in gene sequencing have generated enthusiasm for evaluating personalized cancer medicine strategies using genomic profiling. We assessed the feasibility of incorporating real‐time analysis of somatic mutations within exons of 19 genes into patient management. Blood, tumor biopsy and archived tumor samples were collected from 50 patients recruited from four cancer centers. Samples were analyzed using three technologies: targeted exon sequencing using Pacific Biosciences PacBio RS, multiplex somatic mutation genotyping using Sequenom MassARRAY and Sanger sequencing. An expert panel reviewed results prior to reporting to clinicians. A clinical laboratory verified actionable mutations. Fifty patients were recruited. Nineteen actionable mutations were identified in 16 (32%) patients. Across technologies, results were in agreement in 100% of biopsy specimens and 95% of archival specimens. Profiling results from paired archival/biopsy specimens were concordant in 30/34 (88%) patients. We demonstrated that the use of next generation sequencing for real‐time genomic profiling in advanced cancer patients is feasible. Additionally, actionable mutations identified in this study were relatively stable between archival and biopsy samples, implying that cancer mutations that are good predictors of drug response may remain constant across clinical stages.
Addition of interferon‐α to the p53‐SLP® vaccine results in increased production of interferon‐γ in vaccinated colorectal cancer patients: A phase I/II clinical trial
Authors: Zeestraten Eliane C.M. , Speetjens Frank M. , Welters Marij J.P. , Saadatmand Sepideh , Stynenbosch Linda F.M. , Jongen Rogier , Kapiteijn Ellen , Gelderblom Hans , Nijman Hans W. , Valentijn A. Rob P.M. , Oostendorp Jaap , Fathers Lorraine M. , Drijfhout Jan W. , van de Velde Cornelis J.H. , Kuppen Peter J.K. , van der Burg Sjoerd H. , Melief Cornelis J.M. 
Published: September 2012

AbstractWe previously established safety and immunogenicity of a p53 synthetic long peptides (p53‐SLP®) vaccine. In the current trial, we investigated whether combination of interferon‐alpha (IFN‐α) with p53‐SLP® is both safe and able to improve the induced p53‐specific IFN‐γ response. Eleven colorectal cancer patients successfully treated for metastatic disease were enrolled in this study. Of these, nine patients completed follow‐up after two injections with p53‐SLP® together with IFN‐α. Safety and p53‐specific immune responses were determined before and after vaccination. Furthermore, cryopreserved PBMCs were compared head‐to‐head to cryopreserved PBMCs obtained in our previous trial with p53‐SLP® only. Toxicity of p53‐SLP® vaccination in combination with IFN‐α was limited to Grade 1 or 2, with predominantly small ongoing swellings at the vaccination site. All patients harbored p53‐specific T cells after vaccination and most patients showed p53‐specific antibodies. Compared to the previous trial, addition of IFN‐α significantly improved the frequency of p53‐specific T cells in IFN‐γ ELISPOT. Moreover, in this trial, p53‐specific T cells were detectable in blood samples of all patients in a direct ex vivo multiparameter flowcytometric assay, opposed to only 2 of 10 patients vaccinated with p53‐SLP® only. Finally, patients in this trial displayed a broader p53‐specific immunoglobulin‐G response, indicating an overall better p53‐specific T‐helper response. Our study shows that p53‐SLP® vaccination combined with IFN‐α injection is safe and capable of inducing p53‐specific immunity. When compared to a similar trial with p53‐SLP® vaccination alone the combination was found to induce significantly more IFN‐γ producing p53‐specific T cells.
Distressing Adverse Events After Antidepressant Switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: Influence of Adverse Events During Initial Treatment with Citalopram on Development of Subsequent Adverse Events with an Alternative Antidepressant
Authors: Katz Aaron J. , Dusetzina Stacie B. , Farley Joel F. , Ellis Alan R. , Gaynes Bradley N. , Castillo Wendy C. , Stürmer Til , Hansen Richard A. 
Published: September 2012

Study ObjectiveTo determine whether distressing adverse events (DAEs) experienced during initial antidepressant treatment are associated with subsequent DAEs after switching to a second antidepressant.DesignSecondary analysis of data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.SettingPrimary care and psychiatric care facilities.PatientsA total of 727 outpatients aged 18–75 years with nonpsychotic major depressive disorder who failed first‐step therapy with citalopram and were switched to second‐step monotherapy with an alternative antidepressant.Measurements and Main ResultsIn the STAR*D trial, patient‐reported DAEs were entered into the Patient‐Rated Inventory of Side Effects (PRISE). In this secondary analysis, data from PRISE were used to determine the incidence of DAEs during first‐step treatment with citalopram and second‐step treatment with sustained‐release bupropion, sertraline, or extended‐release venlafaxine. Regression models were used to compare the risk of adverse events during second‐step treatment between those who reported similar adverse events during first‐step treatment and those who did not, while controlling for potential confounders. Of the 727 patients analyzed, DAEs were reported by 514 patients (70.7%) during first‐step treatment and 626 (86.1%) during second‐step treatment; no significant differences were observed among the three second‐step treatment groups. Overall, patients reporting DAEs during first‐step treatment were more likely to report DAEs during second‐step treatment (risk ratio [RR] 1.11, 95% confidence interval [CI] 1.03–1.20). After controlling for confounders, patients were significantly more likely to report DAEs specific to a body function or organ system, such as those involving the genitourinary system (RR 3.39, 95% CI 2.41–4.78) or sexual functioning (RR 2.75, 95% CI 2.29–3.29), if the patients had reported similar events during initial treatment.ConclusionPatients who experienced DAEs with initial antidepressant treatment were likely to report similar adverse events after switching to an alternative antidepressant, even when subsequent treatment is from a different class of antidepressants.
Severe Prolonged Sedation Associated with Coadministration of Protease Inhibitors and Intravenous Midazolam During Bronchoscopy
Authors: Hsu Alice Jenh , Carson Kathryn A. , Yung Rex , Pham Paul A. 
Published: September 2012

Study ObjectiveTo determine whether human immunodeficiency virus (HIV)‐positive patients who received intravenous midazolam during an inpatient bronchoscopy procedure were more likely to experience severe prolonged sedation if they were taking antiretroviral therapy that included a protease inhibitor versus those who were not taking any antiretroviral therapy.DesignRetrospective cohort study.SettingTertiary care academic medical center.PatientsTwo hundred forty‐one HIV‐positive adults who received intravenous midazolam while undergoing bronchoscopy between January 1, 2003, and December 31, 2006, were analyzed; 51 patients were taking an antiretroviral regimen that included a protease inhibitor (exposed group), whereas 190 patients were not taking any antiretroviral agents (nonexposed group).Measurements and Main ResultsPatient demographics, medication administration records, and bronchoscopy data were collected from electronic databases and patient medical records. The exposed and nonexposed groups had similar demographic characteristics except that patients in the exposed group had lower HIV viral loads and were less likely to have altered mental status or respiratory distress before bronchoscopy. In addition, the exposed group had a higher proportion of males and patients with hepatitis B or C virus coinfection. The incidence of severe prolonged sedation was 9.80% in the exposed group versus 1.58% in the nonexposed group (relative risk [RR] 6.21, 95% confidence interval [CI] 1.53–25.12). Specific protease inhibitors associated with severe prolonged sedation were atazanavir‐ritonavir and lopinavir‐ritonavir. Length of hospital stay was approximately 3 days longer in the exposed group compared with the nonexposed group.ConclusionAlthough the interaction between intravenous midazolam and protease inhibitors is well known, this study was the first systematic evaluation, to our knowledge, of the risk of severe prolonged sedation in a cohort of hospitalized HIV‐positive patients. Coadministration of protease inhibitors with intravenous midazolam was associated with severe prolonged sedation as well as increased length of hospital stay. Therefore, concomitant use of these drugs should be closely monitored, or alternative sedatives for procedural sedation should be considered.
Immunoassay Cross‐Reactivity of Phenylephrine and Methamphetamine
Authors: Curtin Lindsay B. , Cawley Michael J. 
Published: September 2012

Phenylephrine, an α1‐adrenergic agonist, and methamphetamine, a prescription drug and substance of abuse, have similar chemical structures and thus have the potential to cross‐react in qualitative screening tools such as a urine drug screening (UDS) performed by immunoassay. This cross‐reactivity may yield a false‐positive result that may affect the provision of care in certain patient populations and clinical situations. We describe a 36‐year‐old woman with confirmed brain death after a short hospital stay who had an initial UDS that was negative for methamphetamine. The patient was assessed for potential organ donation, which included obtaining a follow‐up UDS. A urine sample was obtained after being hospitalized for 36 hours, which tested positive for methamphetamine, with no suspected ingestion of the target substance. Confirmatory laboratory testing indicated that intravenous phenylephrine and its metabolites were the likely cause of the false‐positive UDS. However, the patient was not deemed to be a suitable candidate for organ donation, but clear documentation of the reason for denial of organ donation was not available in the patient's medical record. To our knowledge, this is the first case published in the English‐language literature that describes the clinical occurrence of apparent immunoassay cross‐reactivity of methamphetamine and phenylephrine that resulted in a false‐positive UDS for methamphetamine. In addition, this report describes the potential implications of this situation on clinical care, including organ donation acceptance. Toxicology screening in the emergency department and intensive care unit is a tool to assist in the diagnosis of medical conditions, but it may not always be reliable. Therefore, positive immunoassay results that may change the management of a patient's condition should be quickly verified with confirmatory testing to minimize unfavorable consequences.
Influence of Pill Burden and Drug Cost on Renal Function After Transplantation
Authors: Hardinger Karen L. , Hutcherson Timothy , Preston David , Murillo Daniel 
Published: September 2012

Study ObjectiveTo determine the influence of pill burden and drug cost on outcomes after renal transplantation.DesignRetrospective medical record review.SettingKidney and pancreas transplantation center.PatientsSixty‐eight adults who underwent kidney or kidney‐pancreas transplantation during 2007.Measurements and Main ResultsThe median pretransplantation pill burden was 15 pills/day, which increased to 25 pills/day at 1 month after transplantation and returned to 16 pills/day by 1 year after transplantation. Pretransplantation pill burden was lower than the burden at 1, 3, 6, 12, and 24 months after transplantation (p<0.05). The mean pretransplantation drug cost of $1918/month was lower than the cost at 1 month after transplantation ($2564/mo, p=0.04) but was similar thereafter. Higher pretransplantation pill burden was associated with increased serum creatinine concentration at 6 months after transplantation (r=0.288, p=0.017). Higher pill burdens at 1 month (r=0.364, p=0.002), 3 months (r=0.332, p=0.006), and 6 months (r=0.374, p=0.002) were associated with increased 3‐month serum creatinine concentration. Higher drug costs were associated with increased serum creatinine concentrations throughout the study.ConclusionHigher pretransplantation pill burden and higher drug cost may be associated with poor renal function after transplantation. Further study addressing factors associated with nonadherence is needed.
Use of the Chromogenic Factor X Assay in Patients Transitioning from Argatroban to Warfarin Therapy
Authors: Austin Jennifer H. , Stearns Candace R. , Winkler Anne M. , Paciullo Christopher A. 
Published: September 2012

Study ObjectiveTo assess the correlation between the chromogenic factor X assay and the international normalized ratio (INR) in patients transitioning from argatroban to warfarin therapy.DesignRetrospective medical record review.SettingAcademic medical center and community‐based teaching hospital.PatientsOne hundred thirty‐nine patients who had chromogenic factor X levels measured during the transition from argatroban to warfarin therapy between January 1, 2006, and July 31, 2010.Measurements and Main ResultsThe correlation between chromogenic factor X levels and INRs during the transition period was assessed by calculating the sensitivity, specificity, positive predictive value, and negative predictive value for chromogenic factor X levels that were less than or equal to 45% in predicting a therapeutic INR (2.0–3.5). Patients received an average of 4.4 doses of warfarin before argatroban was discontinued. In 60 patients (43.2%), chromogenic factor X levels were subtherapeutic at the time of argatroban discontinuation. Chromogenic factor X levels could predict a therapeutic INR with a sensitivity of 63.2%, a specificity of 80%, a positive predictive value of 93.5, and a negative predictive value of 32.3. In patients who received 5 or more days of warfarin overlap with argatroban, the sensitivity of chromogenic factor X levels to predict an INR greater than 2.0 was 78.2%, with a specificity of 77.8%, a positive predictive value of 95.6, and a negative predictive value of 36.8. The correlation of chromogenic factor X levels and a therapeutic INR was 18.1%; however, this poor correlation may have been due to increases in the INR values of the patients who received less than 5 days of warfarin overlap with argatroban. During the transition period, nine patients developed thrombi and eight patients experienced clinically significant bleeding.ConclusionMeasuring chromogenic factor X levels is recommended before transitioning patients from argatroban to warfarin therapy. Patients should receive at least 5 days of overlap with warfarin and have a chromogenic factor X level of 45% or less before discontinuing argatroban.